Physician profile
Larry Flake
NPI 1386670917
$20,047.72
in general payments reported to CMS, 2019-2025
63 companies · $2,975 in 2025
The $2,975 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,483 · 2020: $1,824 · 2021: $2,661 · 2022: $4,050 · 2023: $2,800 · 2024: $3,255 · 2025: $2,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,850 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,849.84 |
| Education | $180.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,704.93 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $1,836.16 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,641.00 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,383.12 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,234.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,023.99 | 2019-2025 | Jardiance |
| Pfizer INC. | $979.34 | 2019-2025 | |
| Amgen INC. | $939.15 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $852.87 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $807.36 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $589.86 | 2019-2023 | Belsomra, Steglatro, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $560.03 | 2021-2025 | |
| Allergan, INC. | $480.03 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $401.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.25 | 2019-2025 | Xifaxan |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $307.01 | 2023-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $278.78 | 2023-2024 | Veozah |
| Daiichi Sankyo INC. | $269.36 | 2019-2023 | Injectafer |
| Amarin Pharma, INC. | $253.61 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $215.20 | 2019 | |
| Phathom Pharmaceuticals, INC. | $199.35 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $198.42 | 2019-2024 | Livalo, Seglentis |
| Ironshore Pharmaceuticals INC. | $177.53 | 2019-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $173.67 | 2019-2021 | |
| Corium, LLC | $170.53 | 2021-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $155.67 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $133.28 | 2021 | |
| Lundbeck LLC | $131.27 | 2024-2025 | Rexulti, Vyepti |
| Supernus Pharmaceuticals, INC. | $119.90 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $101.96 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $95.83 | 2023-2025 | Quviviq, Quviviq |
| Dexcom, INC. | $91.77 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $90.45 | 2021-2022 | |
| Abbott Laboratories | $88.43 | 2021-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $85.35 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $84.77 | 2024 | Gemtesa |
| Exact Sciences Corporation | $74.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $72.01 | 2021-2024 | Tirosint, Licart |
| Collegium Pharmaceutical, INC. | $61.64 | 2025 | Jornay Pm |
| Mannkind Corporation | $59.40 | 2022 | |
| Tris Pharma INC | $54.28 | 2021-2023 | Dyanavel Xr |
| Ardelyx, INC. | $49.72 | 2025 | Ibsrela |
| Corcept Therapeutics | $49.04 | 2025 | Korlym |
| Recor Medical INC | $36.50 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abiomed | $31.77 | 2025 | |
| Shire North American Group INC | $31.63 | 2019 | |
| Neos Therapeutics, Lp | $30.04 | 2019 | |
| Inogen, INC. | $27.45 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Horizon Therapeutics Plc | $25.90 | 2019-2023 | Krystexxa |
| Tonix Medicines, INC. | $22.25 | 2025 | Tonmya |
| Vanda Pharmaceuticals INC. | $20.83 | 2024 | Fanapt |
| Antares Pharma, INC. | $20.27 | 2023 | Xyosted, Tlando, Nocdurna |
| Xeris Pharmaceuticals, INC. | $18.96 | 2024 | Keveyis |
| Itamar Medical INC | $18.42 | 2023 | Watchpatone |
| Jazz Pharmaceuticals INC. | $18.36 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.13 | 2022 | |
| Harmony Biosciences LLC | $16.26 | 2023 | Wakix |
| Boston Scientific Corporation | $16.05 | 2024 | |
| Adlon Therapeutics L.P. | $15.78 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.51 | 2025 | Caplyta |
| Upsher-Smith Laboratories LLC | $11.83 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.50 | 2020 | |
| Eisai INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Flake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.